KR20230077349A - Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient - Google Patents
Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient Download PDFInfo
- Publication number
- KR20230077349A KR20230077349A KR1020210164533A KR20210164533A KR20230077349A KR 20230077349 A KR20230077349 A KR 20230077349A KR 1020210164533 A KR1020210164533 A KR 1020210164533A KR 20210164533 A KR20210164533 A KR 20210164533A KR 20230077349 A KR20230077349 A KR 20230077349A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- preparation example
- skin
- improving skin
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 239000002537 cosmetic Substances 0.000 title claims abstract description 36
- 230000037303 wrinkles Effects 0.000 title claims abstract description 34
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 240000001008 Dimocarpus longan Species 0.000 title claims description 19
- 235000003130 Arctium lappa Nutrition 0.000 title description 6
- 244000131360 Morinda citrifolia Species 0.000 title description 5
- 235000017524 noni Nutrition 0.000 title description 5
- 240000005528 Arctium lappa Species 0.000 title description 2
- 235000000525 Dimocarpus longan Nutrition 0.000 title description 2
- 235000008898 Morinda citrifolia Nutrition 0.000 title description 2
- 241000534017 Saururus chinensis Species 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 22
- 230000037394 skin elasticity Effects 0.000 claims abstract description 16
- 230000006872 improvement Effects 0.000 claims abstract description 13
- 235000000235 Euphoria longan Nutrition 0.000 claims description 17
- 235000020729 noni extract Nutrition 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 235000019714 Triticale Nutrition 0.000 claims description 4
- 241000228158 x Triticosecale Species 0.000 claims description 4
- 241000332371 Abutilon x hybridum Species 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 74
- 238000004519 manufacturing process Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 12
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- -1 for example Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 206010040880 Skin irritation Diseases 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 230000036556 skin irritation Effects 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010050808 Procollagen Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 231100000344 non-irritating Toxicity 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241000208843 Arctium Species 0.000 description 4
- 235000008078 Arctium minus Nutrition 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000221079 Euphorbia <genus> Species 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000019206 astragalus extract Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 241001126856 Scytosiphon lomentaria Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 우방자, 노니, 용안 및 삼백초의 혼합추출물을 유효성분으로 함유하는 피부주름개선 및 탄력증진 효과를 갖는 화장료 조성물에 관한 것으로서, 보다 상세하게는 본 발명에 따른 혼합추출물이 각 성분을 단독으로 사용한 경우에 비해 피부탄력증진 및 주름개선 효과가 우수하여 탁월한 효과가 있는 화장용 조성물에 관한 것이다.The present invention relates to a cosmetic composition having skin wrinkle improvement and elasticity enhancing effects, containing mixed extracts of Woobangja, Noni, Longan, and Sambaekcho as active ingredients, and more particularly, the mixed extract according to the present invention contains each component alone. It relates to a cosmetic composition having an excellent effect by improving skin elasticity and improving wrinkles compared to the case where the present invention is used.
Description
본 발명은 우방자, 노니, 용안 및 삼백초의 혼합추출물을 유효성분으로 함유하는 피부주름개선 및 탄력증진 효과를 갖는 화장료 조성물에 관한 것이다. 보다 상세하게는 본 발명에 따른 화장료 조성물이 각 성분을 단독으로 사용한 경우에 비해 피부탄력증진 및 주름개선 효과가 우수하여, 피부에 안전하면서도 탁월한 효과가 있는 화장용 조성물로서 유용하게 이용될 수 있다.The present invention relates to a cosmetic composition having an effect of improving skin wrinkles and enhancing skin elasticity, containing a mixed extract of Woobangja, Noni, Longan, and Sambaekcho as an active ingredient. More specifically, the cosmetic composition according to the present invention has excellent skin elasticity enhancement and wrinkle improvement effects compared to the case of using each component alone, and can be usefully used as a cosmetic composition that is safe and has excellent effects on the skin.
전 세계적으로 건강뿐만 아니라 피부 미용에 대한 관심이 증대되면서 건강한 노년을 보내기 위해 노화에 대한 관심이 높아지고 있다. 피부 노화는 내인성 노화와 외인성 노화로 분류된다. 내인성 노화는 시간이 지남에 따라 진행되는 자연적인 노화를 말하고, 외인성 노화는 자외선, 담배 연기, 미세먼지 등과 같은 환경인자들에 의해 진행되는 노화를 말한다. 특히 자외선 노출은 외인성 노화의 주요 원인이며 광노화라고도 한다. 광노화는 피부 노화의 80%를 차지하며 광노화 된 피부는 주름, 탄력 손실, 건조, 거친 외관 및 색소 침착 등의 특징을 보인다. As interest in skin beauty as well as health increases worldwide, interest in aging is increasing in order to live a healthy old age. Skin aging is classified into intrinsic aging and extrinsic aging. Endogenous aging refers to natural aging that progresses over time, and extrinsic aging refers to aging that is progressed by environmental factors such as ultraviolet rays, cigarette smoke, and fine dust. In particular, exposure to ultraviolet rays is a major cause of extrinsic aging and is also called photoaging. Photoaging accounts for 80% of skin aging, and photoaged skin is characterized by wrinkles, loss of elasticity, dryness, rough appearance and pigmentation.
자외선은 UVA(320-400 nm)와 UVB (280-320 nm)로 크게 구분되며, 그중 UVB는 피부 표피까지 침투하며, 에너지가 크기 때문에 피부노화에 큰 영향을 미친다. UVB에 노출된 피부에서는 싱글렛 옥시전(1O2), 수퍼옥사이드 음이온 라디칼(O2 -), 과산화수소(H2O2), 히드록실 라디칼(·OH), 알콕실 라디칼(OR) 및 과산화 라디칼(·OOR) 등 다양한 종류의 활성산소종(reactive oxygen species, ROS)이 생성된다. 활성산소는 세포 내 손상과 분자 신호 등의 다양한 반응에 관여하는 반응성이 큰 분자로서 단백질 산화, DNA 손상, 지질과산화 반응 개시뿐만 아니라 matrixmetalloproteinases(MMPs)들의 분비를 촉진시켜 콜라겐 또는 젤라틴 등의 세포외 기질 분해를 유도하여 피부노화를 가속화시킬 수 있다.Ultraviolet rays are broadly classified into UVA (320-400 nm) and UVB (280-320 nm). In skin exposed to UVB, singlet oxygen ( 1 O 2 ), superoxide anion radical (O 2 - ), hydrogen peroxide (H 2 O 2 ), hydroxyl radical ( OH), alkoxyl radical (OR) and peroxidation Various types of reactive oxygen species (ROS) such as radicals (· OOR) are generated. Reactive oxygen species are highly reactive molecules involved in various reactions such as intracellular damage and molecular signals. They not only initiate protein oxidation, DNA damage, and lipid peroxidation reactions, but also stimulate the secretion of matrix metalloproteinases (MMPs) to form extracellular matrix such as collagen or gelatin. It can induce decomposition and accelerate skin aging.
MMPs에는 구조와 기능적 특성에 따라 콜라게나아제(collagenase), 겔라티나아제(gelatinase), 스트로멜리신(stromelysin) 등으로 나누어진다. MMP-1은 collagenase Ⅰ으로 알려져 있으며, type Ⅰ과 Ⅲ collagen을 기질로 하며 MMP-3은 stromelysin Ⅰ으로 type Ⅳ collagen을 기질로 하여 콜라겐을 조각으로 분해한다. MMP-2는 겔라티나아제로 이 또한 피부 진피를 구성하는 기질들을 분해하여 피부 노화에 주요한 역할을 한다. 그러므로 피부에서 생성되는 과잉의 활성산소의 생성을 억제하여 피부를 구성하는 기질 물질인 콜라젠과 엘라스틴을 분해하는 MMPs의 발현을 억제하는 소재의 개발은 기능성 화장품 연구에 있어서 매우 중요한 것으로 평가되고 있다.MMPs are divided into collagenase, gelatinase, and stromelysin according to their structural and functional properties. MMP-1 is known as collagenase Ⅰ, and type Ⅰ and Ⅲ collagen are used as substrates. MMP-3 is stromelysin Ⅰ, which uses type 4 collagen as a substrate to break down collagen into fragments. MMP-2 is a gelatinase that also plays a major role in skin aging by degrading the substrates constituting the skin dermis. Therefore, the development of a material that suppresses the expression of MMPs that decompose collagen and elastin, which are matrix substances constituting the skin, by suppressing the generation of excess active oxygen generated in the skin is evaluated as very important in functional cosmetics research.
식물 추출물을 포함하여 피부 주름 개선 효과를 갖는 화장료 조성물에 대한 특허들이 다수 공개되어 있다. 한국등록특허 제10-1574248호에서는 왕호장(Reynoutria sachalinensis) 추출물을 유효성분으로 포함하는 피부 주름개선용 화장료 조성물을 개시한다. 또한, 한국 등록특허 제10-1693931호에서는 고리매 (Scytosiphon lomentaria) 추출물을 유효성분으로 포함하는 주름개선용 화장료 조성물을 개시한다.A number of patents on cosmetic compositions containing plant extracts having a skin wrinkle improvement effect have been published. Korean Patent Registration No. 10-1574248 discloses a cosmetic composition for improving skin wrinkles containing an extract of Reynoutria sachalinensis as an active ingredient. In addition, Korean Patent Registration No. 10-1693931 discloses a cosmetic composition for improving wrinkles containing an extract of Scytosiphon lomentaria as an active ingredient.
본 발명은 여러 천연 식물 추출물들 중에서 종래 기술보다 탄력개선 능력이 탁월하고, 피부 주름 완화에 도움이 되는 물질을 찾던 도중에 우방자, 노니, 용안 및 삼백초의 추출물을 혼합하하는 경우, 피부탄력증진 및 주름개선에 도움을 줄 수 있음을 확인하였다.The present invention, among several natural plant extracts, has excellent elasticity improvement ability compared to the prior art, and when extracts of Woobangja, Noni, Longan, and Sambaekcho are mixed while looking for a substance helpful in relieving skin wrinkles, skin elasticity enhancement and wrinkles It was confirmed that it can help improve.
따라서 본 발명의 목적은 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물을 유효성분으로 함유하는 피부탄력증진 및 주름개선용 화장용 조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide a cosmetic composition for enhancing skin elasticity and improving wrinkles containing a mixture of extracts of Raisinia extract, Noni extract, Longan extract and Sambaekcho extract as active ingredients.
상기 목적을 달성하기 위하여, 본 발명은 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물을 유효성분으로 함유하는 피부 주름개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for improving skin wrinkles containing a mixed extract of Euphorbia extract, Noni extract, Longan extract and Sambaekcho extract as an active ingredient.
바람직하게는 상기 화장료 조성물은 피부 탄력 개선 효과를 갖는다. Preferably, the cosmetic composition has an effect of improving skin elasticity.
또한 바람직하게는, 상기 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물은 1~10 : 1~10 : 1~10 : 1~10의 중량비로 함유될 수 있으며, 보다 또한 바람직하게는 1:1:1:1의 중량비로 함유되는 것이 좋다. Also preferably, the Astragalus extract, Noni extract, Longan extract, and Sambaekcho extract may be contained in a weight ratio of 1 to 10: 1 to 10: 1 to 10: 1 to 10, and more preferably 1: 1: It is preferable to contain it in a weight ratio of 1:1.
또한 바람직하게는, 상기 혼합추출물은 화장료 조성물 전체에 대하여 0.01~30 중량% 포함된다.Also preferably, the mixed extract is included in an amount of 0.01 to 30% by weight based on the total cosmetic composition.
바람직하게는, 상기 화장료 조성물은 영양화장수, 영양에센스 및 영양크림으로 이루어진 군에서 선택되는 어느 하나일 수 있다.Preferably, the cosmetic composition may be any one selected from the group consisting of nutrient lotion, nutrient essence and nutrient cream.
본 발명에 의한 우방자, 노니, 용안 및 삼백초 추출물의 혼합추출물을 함유하는 화장료 조성물은 엘라스타제의 활성을 저해할 뿐 아니라, MMP-1 생성 억제 효과가 우수하여 주름개선 효과가 탁월하다. 또한, 우방자, 노니, 용안 및 삼백초 추출물의 혼합추출물을 함유하는 본 발명의 조성물은 피부탄력증진에도 효과적이므로 피부탄력증진 및 주름개선용 화장료로 유용하게 사용될 수 있다.The cosmetic composition containing the mixed extract of Eubangja, Noni, Longan, and Sambaekcho extracts according to the present invention not only inhibits the activity of elastase, but also has an excellent anti-wrinkle effect because of its excellent inhibitory effect on MMP-1 production. In addition, the composition of the present invention containing a mixed extract of Eubangja, Noni, Longan, and Sambaekcho extracts is effective in improving skin elasticity, so it can be usefully used as a cosmetic for improving skin elasticity and wrinkles.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 하기의 정의를 가지며 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미에 부합된다. 또한, 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다.All technical terms used in the present invention, unless otherwise defined, have the following definitions and correspond to the meanings commonly understood by those of ordinary skill in the art related to the present invention. In addition, although preferred methods or samples are described in this specification, those similar or equivalent thereto are also included in the scope of the present invention.
용어 "약"이라는 것은 참조 양, 수준, 값, 수, 빈도, 퍼센트, 치수, 크기, 양, 중량 또는 길이에 대해 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 또는 1% 정도로 변하는 양, 수준, 값, 수, 빈도, 퍼센트, 치수, 크기, 양, 중량 또는 길이를 의미한다.The term "about" means a reference amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length of 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, means an amount, level, value, number, frequency, percentage, dimension, size, quantity, weight or length that varies by 4, 3, 2 or 1%.
본 명세서를 통해, 문맥에서 달리 필요하지 않으면, "포함하다" 및 "포함하는"이란 말은 제시된 단계 또는 구성요소, 또는 단계 또는 구성요소들의 군을 포함하나, 임의의 다른 단계 또는 구성요소, 또는 단계 또는 구성요소들의 군이 배제되지는 않음을 내포하는 것으로 이해하여야 한다.Throughout this specification, unless the context requires otherwise, the terms "comprise" and "comprising" include a given step or element, or group of steps or elements, but any other step or element, or It is to be understood that steps or groups of components are not excluded.
본 발명은 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin wrinkles containing a mixture of extracts of Euphorbia japonica extract, noni extract, longan extract, and triticale extract as an active ingredient.
우방자(Arctium lappa)는 국화과에 속한 우엉의 성숙한 종자를 건조한 것이다. 우엉은 높이가 50~150cm이고, 곧은 뿌리가 30~60cm까지 자라며 끝에서 줄기가 나온다. 겉면은 짙은 녹색이지만 뒷면에 흰 솜털이 빽빽이 나며, 가장자리에 이 모양의 톱니가 있다. 꽃은 7~8월에 피는데 검은 자줏빛이 돌며, 두화는 가지 끝에 산방꽃차례로 달린다. 총포는 둥글고 포는 바늘 모양이며 끝이 갈고리처럼 생긴다. 꽃은 관상화이고 종자는 검은색이며 관모는 갈색이다. 열매는 수과로서 9월에 익는다. 우엉의 뿌리에는 이눌린과 약간의 팔미트산이 들어 있는 것으로 알려져 있다. 유럽에서는 이뇨제와 발한제로 쓰고 종자는 부기가 있을 때 이뇨제로 사용하며, 인후통과 독충의 해독제로 쓴다. 우엉의 씨앗은 우방자라고 하며 풍열을 소통시켜 ?m어지게 하고 폐기를 통하게 하며 두진이 돋아나게 하고 부기를 가라앉히며 해독하는 효능이 있는 약재로도 쓰인다. Arctium lappa is the dried mature seed of burdock belonging to the Asteraceae family. Burdock is 50~150cm high, straight roots grow up to 30~60cm, and a stem comes out from the end. The outer surface is dark green, but white downy hairs grow densely on the back side, and there are tooth-shaped sawtooth edges. Flowers bloom in July-August, and are black purplish, and douhwa hangs in corymbose at the end of branches. The guns are round, the guns are needle-shaped, and the ends are like hooks. Flowers are tubular, seeds are black, and hairs are brown. The fruit is an achene and ripens in September. Burdock root is known to contain inulin and some palmitic acid. In Europe, it is used as a diuretic and diaphoretic, and the seeds are used as a diuretic when there is swelling, and as an antidote for sore throat and poisonous insects. The seed of burdock is called Ubangja and is also used as a medicinal material that has the effect of communicating wind heat, making it swollen, disposing of waste, sprouting papules, relieving swelling, and detoxifying.
또한, 노니(Morinda citrifolia)는 인도네시아 모로카 제도 원산의 약용식물이다. 약 6000 여년전부터 열매 및 잎은 식용이나 약용으로 이용되고, 뿌리 및 줄기는 염색에 이용되었으며, 약 2000년 전에 해양민족과 함께 태평양 연안으로 전파되었다. 인도네시아에서는 멘크드, 파체, 디바 등으로 불리며, 만병에 효과가 있는 약으로서 지금도 쟈무라는 전통치료약으로 이용되고 있다.In addition, Noni ( Morinda citrifolia ) is a medicinal plant native to Morocca Islands, Indonesia. From about 6,000 years ago, fruits and leaves have been used for food or medicine, and roots and stems have been used for dyeing. In Indonesia, it is called Menkd, Pache, Diva, etc., and as a medicine effective for all diseases, Jamura is still used as a traditional medicine.
또한, 용안(Euphoria longana)은 무환자나무과 식물로서 열대지방에서 자라는 식물이다. 잎은 어긋나고 두껍고 긴 타원형으로서 길이 15-45㎝이고 가장자리가 밋밋하다. 꽃은 4월에 노란빛을 띤 흰색으로 픽 지름 3-6㎝로서 향기가 있으며, 1,000여 개가 원추꽃차례에 달린다.In addition, longan ( Euphoria longana ) is a plant that grows in the tropics as an aphid plant. Leaves are alternate, thick and long oval, 15-45 cm long, with flat edges. Flowers are yellowish white in April, 3-6 cm in diameter, fragrant, and about 1,000 flowers hang on a panicle.
상기 삼백초(Saururus chinensis)는 제주도와 지리산 일부 지역에서 자라나는 다년생 초본이다. 생육 환경은 습기가 많은 계곡의 바람이 잘 통하고 공중습도가 높으며 반그늘인 곳에서 자란다. 키는 50~100 ㎝, 잎은 길이 5~15 ㎝, 폭은 0.3~0.8 ㎝로 긴 타원형이며, 어긋나게 난다. 잎 표면은 연한 녹색이고 뒷면은 연한 백색이며 꽃이 필 무렵에는 윗부분의 잎 2~3개가 백색으로 변하고 5~7개의 맥이 있으며, 끝은 뾰족하고 가장자리는 밋밋하다. 뿌리는 백색으로 흙 속으로 파고들며, 옆으로 뻗으면서 자란다. 꽃은 백색으로 아래로 처지다가 끝 부분은 위로 올라가며, 잎과 마주나고 길이는 10~15㎝이고, 꼬불꼬불한 털이 있다. 열매는 9~10월 경에 꽃망울에 한 개씩이 둥글게 달린다. 관상용으로 쓰이고, 꽃을 포함한 잎과 줄기 뿌리는 약재로 쓰인다.The three baekcho ( Saururus chinensis ) is a perennial herb that grows in some areas of Jeju Island and Jirisan Mountain. The growth environment is well-ventilated in a humid valley, and grows in a semi-shaded place with high air humidity. The height is 50-100 cm, the leaves are 5-15 cm long, 0.3-0.8 cm wide, long oval, and grow alternately. The surface of the leaf is light green and the back side is light white. When the flower blooms, 2-3 upper leaves turn white and have 5-7 veins, the tip is sharp and the edge is flat. The root is white, digs into the soil, and grows while extending to the side. The flower is white, droops downward, then the end part rises upward, faces the leaf, is 10 to 15 cm long, and has curly hairs. The fruit hangs in a round shape on a flower bud in September-October. It is used for ornamental purposes, and leaves including flowers and stems and roots are used as medicine.
또한, 본 발명의 일 실시형태에 따르면, 본 발명은 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물을 유효성분으로 함유하는 피부탄력증진용 화장료 조성물을 제공한다.In addition, according to one embodiment of the present invention, the present invention provides a cosmetic composition for enhancing skin elasticity containing a mixed extract of chinensis extract, noni extract, longan extract, and triticale extract as an active ingredient.
상기 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물은 단독으로도 콜라겐 생성 효과 및 콜라게네이즈 저해 효과를 갖지므로 단독으로 주름 개선용 화장품으로 이용될 수 있다. 그러나, 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물을 혼합할 경우 더욱 우수한 콜라겐 생성 효과 및 콜라게네이즈 저해 효과를 가지므로, 함께 혼합하여 이용되는 것이 바람직하다.Since the extracts of Eupinia extract, Noni extract, Longan extract, and Sambaekcho extract alone have collagen production and collagenase inhibitory effects, they can be used alone as cosmetic products for improving wrinkles. However, since it has a more excellent collagen production effect and collagenase inhibitory effect when Astragalus extract, Noni extract, Longan extract and Sambaekcho extract are mixed, it is preferable to mix them together.
바람직하게는, 상기 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물은 1~10 : 1~10 : 1~10 : 1~10의 중량비로 함유될 수 있으며, 보다 바람직하게는 1:1:1:1의 중량비로 함유되는 것이 좋다. 그러나, 함량비율은 제품의 특성에 따라 다양한 중량비로 혼합될 수 있다.Preferably, the Eubangia extract, Noni extract, Longan extract and Sambaekcho extract may be contained in a weight ratio of 1 to 10: 1 to 10: 1 to 10: 1 to 10, more preferably 1: 1: 1: It is preferable to contain it in a weight ratio of 1. However, the content ratio may be mixed in various weight ratios depending on the characteristics of the product.
상기 각 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있으나, 바람직하게는 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매를 이용한 용매 추출법 (b) 이산화탄소에 의한 감압 및 고온에 의한 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한다. 본 발명에서는 바람직하게는 추출용매를 이용한 용매 추출법을 이용하였다. Each of the above extracts may be prepared according to a conventional method known in the art, that is, under conventional conditions of temperature and pressure, using a conventional solvent, but preferably (a) water and 1 to 4 carbon atoms. Anhydrous or hydrous lower alcohols (e.g. methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and a solvent extraction method using a solvent selected from the group consisting of mixtures thereof, (b) supercritical extraction method using carbon dioxide under reduced pressure and high temperature, or (c) ultrasonic extraction method. In the present invention, a solvent extraction method using an extraction solvent is preferably used.
본 발명에서 상기 추출물은 다양한 추출용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올 (예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 1종 이상의 추출 용매를 사용하여 얻을 수 있으며, 바람직하게는 에탄올, 70%(v/v) 에탄올 또는 물을 사용하여 얻어진 것이고, 가장 바람직하게는 70%(v/v) 에탄올을 사용하여 얻어진 것이다. 한편, 본 발명의 추출물은 상기한 추출 용매 뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다. In the present invention, the extract is a variety of extraction solvents, for example, water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol , It can be obtained using one or more extraction solvents selected from the group consisting of glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof, preferably ethanol, 70% (v/v) ethanol or water, most preferably 70% (v/v) ethanol. On the other hand, it is obvious to those skilled in the art that the extract of the present invention can be obtained using not only the above extraction solvent, but also other extraction solvents exhibiting substantially the same effect.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 및 발효 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리하거나 자연 상태나 각종 미생물을 이용한 발효산물에 의한 추출물 등, 추가적으로 실시된 다양한 정제 및 추출방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함된다.In addition, the extract of the present invention includes not only the extract by the above-described extraction solvent, but also an extract subjected to conventional purification and fermentation processes. For example, decompression by carbon dioxide, extraction by supercritical extraction by high temperature, extraction by ultrasonic extraction, separation using an ultrafiltration membrane with a constant molecular weight cut-off value, various chromatography (size, charge, hydrophobicity or affinity) Active fractions obtained through various additional purification and extraction methods, such as separation by a method for separation according to sex) or extracts obtained by natural conditions or fermentation products using various microorganisms, are also included in the extract of the present invention.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 유효 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.Ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the active ingredients as active ingredients, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances. adjuvants, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩, 마사지크림 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition of the present invention can be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , It may be formulated into oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray, etc., but is not limited thereto. More specifically, it may be prepared in the form of softening lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다. When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing formulation, or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, removed, or washed with water. As specific examples, the soap is liquid soap, powder soap, solid soap, and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel, and cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream. , cleansing lotion, cleansing water and cleansing gel, but are not limited thereto.
이하 비한정적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 단 하기 실시예는 본 발명을 예시하기 위한 의도로 기재한 것으로서 본 발명의 범위는 하기 실시예에 의하여 제한되는 것으로 해석되지 아니한다.Hereinafter, the present invention will be described in more detail through non-limiting examples. However, the following examples are intended to illustrate the present invention, and the scope of the present invention is not to be construed as being limited by the following examples.
제조예 1: 우방자추출물의 제조Preparation Example 1: Preparation of chinensis extract
우방자 100g을 정제수로 세척한 후 건조하고 작은 조각으로 파쇄한 뒤, 여기에 그 건조 중량의 1-10배의 70% 저급알코올을 가한다. 15-35℃에서 5일간 추출한 후 300메쉬 여과포로 여과하고, 다시 와트만 5번 여과지로 여과한 후, 회전 감압증발기로 건조하여, 건조 중량 28.7 g인 우방자 추출물을 얻었다.After washing 100 g of Brussels sprouts with purified water, drying and crushing into small pieces, 70% lower alcohol in an amount of 1 to 10 times its dry weight is added thereto. After extracting at 15-35° C. for 5 days, the mixture was filtered with a 300 mesh filter cloth, again filtered with a Whatman No. 5 filter paper, and then dried with a rotary vacuum evaporator to obtain an extract having a dry weight of 28.7 g.
제조예 2: 노니추출물의 제조Preparation Example 2: Preparation of noni extract
정제수로 세척하고 건조한 노니 열매 100g을 파쇄한 후, 물 1.2 ℓ에 넣고 4-40℃에서 5일간 추출한 후 300 메쉬 여과포로 여과하고, 저온 3-5℃에서 5일간 방치하여 숙성시킨 후 번 여과지로 여과했다. 이 여액을 65℃에서 회전 감암 증발기로 건조하여, 건조 중량 25.13 g의 노니 추출물을 얻었다.After washing with purified water and crushing dried noni fruit, 100g was put into 1.2 ℓ of water, extracted at 4-40℃ for 5 days, filtered with a 300 mesh filter cloth, left at a low temperature of 3-5℃ for 5 days, and then aged with burnt filter paper. Filtered. This filtrate was dried with a rotary vacuum evaporator at 65°C to obtain a noni extract having a dry weight of 25.13 g.
제조예 3: 용안추출물의 제조Preparation Example 3: Preparation of longan extract
정제수로 세척하고 건조한 용안의 열매 100g을 물 1.2L에 넣고 냉각 콘덴서가 장치된 추출기에서 5시간 동안 70-90℃에서 가열하여 추출한 후 300메쉬 여과포로 여과하고, 5-10℃에서 7-10일간 방치하여 숙성시킨 후 와트만 5번 여과지로 여과했다. 이 여액을 65℃에서 회전 감암 증발기로 건조하여, 건조 중량 11.8g을 얻었다.100g of Longan fruit washed with purified water and dried was put into 1.2L of water, extracted by heating at 70-90℃ for 5 hours in an extractor equipped with a cooling condenser, filtered through a 300 mesh filter cloth, and 7-10 days at 5-10℃. After aging by standing, it was filtered with Whatman No. 5 filter paper. This filtrate was dried with a rotary evaporator at 65°C to obtain a dry weight of 11.8 g.
제조예 4: 삼백초추출물의 제조Preparation Example 4: Preparation of Sambaekcho extract
건조된 삼백초 잎을 잘게 자른 후, 건조 중량 100 g을 플라스크에 넣고 정제수 1 L로 냉침 후, 고압멸균장치를 사용(121℃, 15분, 1.5기압) 하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 추출물을 제조하였다.After finely chopping the dried triticale leaves, put 100 g of dry weight in a flask, cool with 1 L of purified water, extract using a high-pressure sterilizer (121 ° C, 15 minutes, 1.5 atm), and filter to remove the residue. was manufactured.
제조예 5 내지 15: 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물 제조Preparation Examples 5 to 15: Mixed extract preparation of Eubangia extract, Noni extract, Longan extract and Sambaekcho extract
우방자, 노니, 용안 및 삼백초의 추출물을 하기 표 1에 제시된 것과 같은 중량 비율로 혼합하여 혼합추출물을 얻었다. 구체적으로 제조예 1 내지 4에서 얻은 각각의 추출물을 20 ㎎/㎖의 농도로 3차 증류수에 녹인 후 각 추출물의 중량비율이 표 1이 되도록 각각의 추출물 수용액을 혼합하여 혼합추출물을 제조하였다.Extracts of Woobangja, Noni, Longan, and Sambaekcho were mixed in a weight ratio as shown in Table 1 below to obtain a mixed extract. Specifically, after dissolving each of the extracts obtained in Preparation Examples 1 to 4 in tertiary distilled water at a concentration of 20 mg/ml, a mixed extract was prepared by mixing the aqueous extracts so that the weight ratio of each extract was in Table 1.
제조예 16 내지 18: 혼합추출물을 함유하는 화장료의 제조Preparation Examples 16 to 18: Preparation of cosmetics containing mixed extracts
본 발명의 혼합추출물을 인체 피부에 직접 적용하였을 때, 우수한 효과를 가지는지 확인하기 위해 하기 표 2의 조성으로 제조예 16 내지 18의 화장료를 제조하였다.When the mixed extract of the present invention was applied directly to human skin, cosmetics of Preparation Examples 16 to 18 were prepared with the composition shown in Table 2 in order to confirm whether they had excellent effects.
실험예 1: 세포독성평가Experimental Example 1: Cytotoxicity evaluation
세포 독성 여부를 확인하기 위해 섬유아세포 NHDF(normal human dermal fibroblast)를 10% FBS(fetal bovine serum)를 첨가한 DMEM 배지에 배양하였으며 96 well plate에 3×104 cells/well의 세포 농도로 접종하여 37℃, 5% CO2 배양기에서 24시간 동안 배양하였다. 배양 후 배지를 제거하고 상기 제조예에서 제조한 추출물을 농도가 1.0% 가 되도록 DMSO(dimethyl sulfoxide)에 희석하여 제조한 희석용액을 처리하여 24시간 배양한 후에 MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazoliumboromide, Sigma, USA)용액을 각 웰에 100 μl 씩 첨가한 후 (3 mg/ml) 4시간 동안 더 배양하였다. 이후 상층액을 제거하고, 150 μl의 DMSO를 첨가한 후, 30분간 shaking하여 생성된 formazan을 녹여 multimicroplate reader(Molecular device Spectra max190)를 이용하여 540 nm에서 흡광도를 측정하였다. 세포생존율은 아래의 식에 따라 계산하였으며 그 결과는 하기의 표 3에 나타내었다.To confirm cytotoxicity, fibroblast NHDF (normal human dermal fibroblast) was cultured in DMEM medium supplemented with 10% FBS (fetal bovine serum), and inoculated in a 96 well plate at a cell concentration of 3×10 4 cells/well. 37 ℃, 5% CO 2 It was cultured for 24 hours in an incubator. After culturing, the medium was removed and the concentration of the extract prepared in the above preparation was diluted in DMSO (dimethyl sulfoxide) to a concentration of 1.0%. After culturing for 24 hours, MTT (3-[4,5-dimethylthiazol -2yl] -2,5-diphenyltetrazolium boromide, Sigma, USA) solution was added to each well by 100 μl (3 mg/ml) and further incubated for 4 hours. Thereafter, the supernatant was removed, 150 μl of DMSO was added, shaken for 30 minutes to dissolve the generated formazan, and absorbance was measured at 540 nm using a multimicroplate reader (Molecular device Spectra max190). Cell viability was calculated according to the formula below, and the results are shown in Table 3 below.
상기 표 3을 보면, 우방자, 노니, 용안 또는 삼백초 각각의 추출물, 또는 이들의 혼합추출물을 적용한 시료 모두 NHDF에 처리하였을 때 95% 이상의 세포생존율을 나타냄에 따라 인간피부유래 섬유아세포의 세포 독성에는 영향을 미치지 않는 것으로 확인되었고, 이에 안전에는 문제가 없는 것을 확인하였다.Referring to Table 3, when all samples applied with extracts of Woobangja, Noni, Longan, or Sambaekcho, or a mixture extract thereof, showed a cell viability of 95% or more when treated with NHDF, the cytotoxicity of human skin-derived fibroblasts was affected. , and it was confirmed that there is no problem with safety.
실험예 2: MMP-1 생성 억제 효과Experimental Example 2: MMP-1 production inhibitory effect
인간피부유래 NHDF 세포를 48 well plate(Nunc, 덴마크)에 각 웰당 1×106 세포가 되도록 접종하고, DMEM 배지 및 37℃, 5% CO2 배양기에서 24시간 동안 배양한 후 상기 제조예 1 내지 15의 추출물 및 이들의 혼합추출물의 최종농도가 1.0% 되게 첨가한 무혈청 DMEM 배지 및 대조군으로 우방자추출물과 노니추출물, 용안추출물, 삼백초추출물이 포함되지 않은 무혈청 DMEM 배지에서 48시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 MMP-1 분석 키트를 이용하여 새로 합성된 MMP-1의 양(ng/ml)을 측정하고, 하기 수학식 2에 따라 MMP-1 생성 억제율을 계산하였으며, 그 결과는 표 4에 나타내었다. 이때, MMP-1 생성 억제율의 양성 대조군으로 TGF-β(10ng/ml, Roche, 미합중국)을 사용하였다.Human skin-derived NHDF cells were inoculated into a 48-well plate (Nunc, Denmark) to be 1×10 6 cells per well, cultured for 24 hours in a DMEM medium and 37° C., 5% CO 2 incubator, and then prepared in Preparation Example 1 to In a serum-free DMEM medium to which the final concentration of the extract of No. 15 and these mixed extracts was added to be 1.0%, and as a control, cultured for 48 hours in a serum-free DMEM medium that did not contain extracts of Raisinia extract, Noni extract, Longan extract, and Sambaekcho extract. did After culturing, the supernatant of each well was collected and the amount (ng/ml) of newly synthesized MMP-1 was measured using an MMP-1 assay kit, and the inhibition rate of MMP-1 production was calculated according to Equation 2 below, The results are shown in Table 4. At this time, TGF-β (10 ng/ml, Roche, USA) was used as a positive control for the inhibition of MMP-1 production.
상기 표 4를 보면, 본 발명 제조예의 우방자, 노니, 용안 또는 삼백초 각각의 추출물과 이들의 혼합추출물을 비교해 볼 때, 혼합추출물인 제조예 11, 14 및 15가 인간 섬유아세포에서 우수한 MMP-1 생성 억제율을 보여주었다. 특히 제조예 15에서 가장 우수한 활성을 나타내었다. 여기서 MMP-1은 콜라겐 분해효소이고, 다양한 외부 자극(자외선) 등으로 인해 발생 되는 스트레스에 의해 발현이 증가되는 단백질이다. 자외선을 받으면 피부세포에 그 합성이 증가되고, 피부의 기질 단백질을 녹이고 분해하는 작용을 하며 자외선을 비롯한 외부자극들이 MMP-1 효소와 합성을 더욱 증가시켜 노화가 촉진되는 작용을 한다. 이 MMP-1 효소의 생성이 억제된다는 것은 피부의 주름 개선에 효과가 있다는 것을 의미한다.Referring to Table 4, when comparing the extracts of Woobangja, Noni, Longan, or Sambaekcho and their mixed extracts in Preparation Examples of the present invention, Preparation Examples 11, 14, and 15, which are mixed extracts, produce excellent MMP-1 in human fibroblasts. inhibition rate was shown. In particular, Preparation Example 15 showed the best activity. Here, MMP-1 is a collagen degrading enzyme, and is a protein whose expression is increased by stress caused by various external stimuli (ultraviolet rays). When exposed to ultraviolet rays, its synthesis increases in skin cells, and it dissolves and decomposes skin matrix proteins, and external stimuli including ultraviolet rays further increase MMP-1 enzyme and synthesis, thereby accelerating aging. The suppression of the production of this MMP-1 enzyme means that it is effective in improving skin wrinkles.
실험예 3: Procollagen type 1 생성 증가 효과Experimental Example 3: Procollagen type 1 production increasing effect
콜라겐은 주로 힘줄, 인대, 피부와 같은 섬유조직에서 발견되는 구조 단백질로 전체 콜라겐 중 1형이 전체 콜라겐의 약 90%를 차지한다. 피부에서는 주름개선, 탄력, 피부손상 회복 등을 담당한다. 본 발명자들은 섬유아세포에서 procollagen type 1의 생성 증가 효능을 확인하기 위해 NHDF 세포를 24 well plate에 접종하여 37℃, 5% CO2 배양기에서 24시간 동안 배양하였다. 이후 상기 제조예에서 제조한 추출물을 시료농도가 1.0% 가 되도록 처리한 후 24시간 동안 배양하였다. 이후에 배양된 세포의 배지를 수거하여 Procollagen type I cpeptide EIA kit (TAKARA, Japan)를 사용하여 procollagen type 1의 양을 측정하였다. 한편, 바닥에 부착되어 있는 세포는 PBS로 세척한 후 1N NaOH로 용해시켜 총 단백질 양을 측정하여, 일정 단백질 당 전구콜라겐 생성량을 계산하였다.Collagen is a structural protein mainly found in fibrous tissues such as tendons, ligaments and skin, and type 1 accounts for about 90% of the total collagen. In the skin, it is responsible for wrinkle improvement, elasticity, and skin damage recovery. The present inventors inoculated NHDF cells into a 24-well plate and cultured them in a 37°C, 5% CO 2 incubator for 24 hours in order to confirm the effect of increasing the production of procollagen type 1 in fibroblasts. Then, the extract prepared in Preparation Example was treated so that the sample concentration was 1.0%, and then cultured for 24 hours. Thereafter, the medium of the cultured cells was collected and the amount of procollagen type 1 was measured using the Procollagen type I cpeptide EIA kit (TAKARA, Japan). On the other hand, the cells attached to the bottom were washed with PBS and then dissolved with 1N NaOH to measure the total amount of protein, and the amount of pre-collagen production per certain protein was calculated.
그 결과를 하기 표 5에 나타내었다.The results are shown in Table 5 below.
상기 표 5를 보면, 본 발명 제조예의 우방자, 노니, 용안 또는 삼백초의 추출물 각각과 이들의 혼합추출물을 비교해 볼 때, 혼합추출물인 제조예 11, 14 및 15가 인간 섬유아세포에서 procollagen type 1의 생성을 효과적으로 증가시키는 것을 확인할 수 있었다. 특히 제조예 15에서 가장 우수한 활성을 나타내었다.Referring to Table 5, when comparing the extracts of Woobangja, Noni, Longan, or Sambaekcho of the present invention and their mixed extracts, Preparation Examples 11, 14, and 15, which are mixed extracts, produced procollagen type 1 in human fibroblasts was found to increase effectively. In particular, Preparation Example 15 showed the best activity.
실험예 4: 피부주름 개선 효과Experimental Example 4: Skin wrinkle improvement effect
본 발명의 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물의 혼합추출물을 함유하는 화장료 조성물의 피부주름 개선 효과를 건강한 30세에서 50세의 여성 40명을 대상으로 측정하였다. 먼저, 네 그룹으로 나누고, A 그룹에는 제조예 16을, B 그룹에는 제조예 17을, C 그룹에는 제조예 18을, D 그룹에는 비교제조예 1을 안면부에 하루 2회씩(아침 및 저녁) 3개월간 도포하였다. 3개월 후 주름의 개선 정도를 주름의 영상 분석을 통해 평가하였다.The skin wrinkle improvement effect of the cosmetic composition containing the mixed extract of Eubangia extract, Noni extract, Longan extract and Sambaekcho extract of the present invention was measured on 40 healthy women aged 30 to 50 years old. First, it is divided into four groups, Preparation Example 16 in Group A, Preparation Example 17 in Group B, Preparation Example 18 in Group C, and Comparative Preparation Example 1 in Group D are applied to the face twice a day (morning and evening) 3 applied for months. After 3 months, the degree of wrinkle improvement was evaluated through image analysis of wrinkles.
주름의 영상분석에 의한 평가는 실험이 시작되기 전 눈 밑의 레플리카를 채취하고 실험이 종료된 직후의 레플리카를 눈 밑의 동일 부위에서 채취하여 영상분석을 통해 주름의 2차원적 분석으로 주름의 밀도를 측정하였다. 영상분석에 의한 주름 밀도의 측정 결과는 사용 전과 비교한 주름 밀도에 대한 감소율로 하기의 표 6에 나타내었다.For the evaluation of wrinkles by image analysis, a replica is taken under the eyes before the experiment begins, and a replica is taken from the same area under the eyes immediately after the experiment is finished, and the density of wrinkles is analyzed by two-dimensional analysis of wrinkles through image analysis. was measured. The wrinkle density measurement results by image analysis are shown in Table 6 below as a reduction rate for wrinkle density compared to before use.
상기 표 6으로부터, 우방자, 노니, 용안 및 삼백초 추출물의 혼합추출물을 함유한 제조예 18의 경우 대조군에 비하여 피부주름 개선 효과가 매우 우수함을 알 수 있었다.From Table 6, in the case of Preparation Example 18 containing the mixed extract of Woobangja, Noni, Longan and Sambaekcho extracts, it was found that the skin wrinkle improvement effect was very excellent compared to the control group.
실험예 5: 피부 탄력 개선 효과Experimental Example 5: Skin elasticity improvement effect
실제 사람 피부에서의 탄력 개선 효과를 시험하기 위하여 다음과 같이 시험하였다. 30세에서 50세의 여성 40명을 대상으로 각각 10명씩 4조로 나누어 아침 저녁 매일 2회씩 8주간 안면에 도포한 후 피부탄력측정기(Cutometer SEM 575, C+K Electronic Co., Germany)를 이용하여 피부 탄력 개선효과를 측정하였으며, 그 결과를 하기 표 7에 나타내었다. 표 7의 결과값은 피부탄력측정기의 피부 점탄성(viscoelasticity)의 성질을 의미한다. 제조예 18의 경우 대조군에 비하여 피부탄력효과가 현저히 좋아짐을 확인하였다.In order to test the effect of improving elasticity in real human skin, the following test was performed. 40 women between the ages of 30 and 50 were divided into 4 groups of 10 each and applied to the face twice daily in the morning and evening for 8 weeks. The skin elasticity improvement effect was measured, and the results are shown in Table 7 below. The result values in Table 7 mean the properties of skin elasticity (viscoelasticity) of the skin elasticity tester. In the case of Preparation Example 18, it was confirmed that the skin elasticity effect was significantly improved compared to the control group.
실험예 6: 피부 일차 자극 평가(patch test)Experimental Example 6: Primary skin irritation evaluation (patch test)
시험 대상자는 본 인체적용시험 기간 중 총 3회 (시험 시작 전, 첩포 제거일, 첩포 제거 후 30분 경과 후) 방문하여 피부 자극 여부를 판정받았다. 첫 방문 시, 시험대상자는 핀 챔버 (Finn chamber, 100×10, EPITEST, 핀란드국)를 이용하여 시험대상자의 등에 피부 첩포 시험을 실시하였다. 시험 대상자 20명을 대상으로 핀 챔버를 이용하여 등에 척추를 중심으로 어깨뼈와 허리선 사이에 시료를 적용하였다.During this human application test period, the test subject visited a total of three times (before the start of the test, on the day of patch removal, and after 30 minutes after removing the patch) to determine whether or not skin irritation was present. At the first visit, the test subject performed a skin patch test on the subject's back using a Finn chamber (100 × 10, EPITEST, Finland). For 20 test subjects, samples were applied between the shoulder blades and the waistline centering on the back spine using a pin chamber.
시험부위를 70% 에탄올로 닦아 내고 건조시킨 다음 시료를 20μl 씩 핀 챔버에 적하시킨 후 시험 부위에 얹어 고정시켰다. 24시간 동안 피부에 첩포 하였으며, 첩포를 제거한 후에는 marking pen으로 시험부위를 표시하여 30분 경과 후에 확대경 (8MC-150, DAZOR, 미합중국)을 이용하여 시험 부위의 홍반 및 부종 유무를 관찰하였다.After wiping the test site with 70% ethanol and drying it, 20 μl of each sample was dropped into the pin chamber, and then placed on the test site and fixed. It was applied to the skin for 24 hours, and after removing the patch, the test site was marked with a marking pen, and after 30 minutes, erythema and edema of the test site were observed using a magnifying glass (8MC-150, DAZOR, USA).
피부반응은 국제접촉피부염연구회 (ICDRG: International Contact Dermatitis Research Group)의 규정 (표 8)에 따라 판정하였으며, 하기 수학식 2에 의하여 평균 피부 반응도를 계산하고 그 결과를 표 9에 나타내었다.The skin reaction was determined according to the regulations (Table 8) of the International Contact Dermatitis Research Group (ICDRG), and the average skin reactivity was calculated by Equation 2 below, and the results are shown in Table 9.
본 실험예 1에서의 피부 자극 정도는 상기 표 2와 같이 평가 기준에 따라 나타내었으며, 피부 자극률은 아래의 계산공식으로 구하여 표 3에 나타내었다.The degree of skin irritation in Experimental Example 1 was shown according to the evaluation criteria as shown in Table 2 above, and the skin irritation rate was obtained by the calculation formula below and shown in Table 3.
[수학식 3][Equation 3]
피부 자극도는, 자극률이 0.0이면 무자극, 0.1~1.0이면 미자극, 1.0~1.7인 경우 경자극, 1.7~2.5인 경우 중자극, 2.5 이상인 경우에는 강자극으로 판정한다.For skin irritation, if the irritation rate is 0.0, it is non-irritating, if it is 0.1~1.0, it is not irritating, if it is 1.0~1.7, it is mild irritation, if it is 1.7~2.5, it is medium stimulation, and if it is 2.5 or more, it is judged as strong irritation.
상기 표 9를 보면, 본 발명의 혼합추출물을 함유하는 화장료에서 피부자극이 나타나지 않아 피부안정성이 우수함을 확인하였다.Looking at Table 9, it was confirmed that the cosmetic composition containing the mixed extract of the present invention did not cause skin irritation and had excellent skin stability.
Claims (5)
상기 혼합추출물은 우방자추출물, 노니추출물, 용안추출물 및 삼백초추출물이 1~10 : 1~10 : 1~10 : 1~10의 중량비로 혼합되는 것을 특징으로 하는 피부 주름 개선용 화장료 조성물.According to claim 1,
The mixed extract is a cosmetic composition for improving skin wrinkles, characterized in that the weight ratio of bellflower extract, noni extract, longan extract and triticale extract is mixed in a weight ratio of 1 to 10: 1 to 10: 1 to 10: 1 to 10.
상기 혼합추출물은 상기 화장료 조성물 전체 중량에 대하여 0.01~30% 중량 함유되는 것을 특징으로 하는 피부 주름 개선용 화장료 조성물.According to claim 1,
The mixed extract is a cosmetic composition for improving skin wrinkles, characterized in that contained 0.01 to 30% by weight based on the total weight of the cosmetic composition.
상기 화장료 조성물은 피부 탄력개선 효과를 갖는 것을 특징으로 하는 피부 주름 개선용 화장료 조성물.According to claim 1,
The cosmetic composition is a cosmetic composition for improving skin wrinkles, characterized in that it has a skin elasticity improvement effect.
상기 화장료 조성물은 영양화장수, 영양에센스 및 영양크림으로 이루어진 군에서 선택되는 어느 하나인, 피부 주름 개선용 화장료 조성물.According to claim 1,
The cosmetic composition is any one selected from the group consisting of nutrient lotion, nutrient essence and nutrient cream, a cosmetic composition for improving skin wrinkles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210164533A KR20230077349A (en) | 2021-11-25 | 2021-11-25 | Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210164533A KR20230077349A (en) | 2021-11-25 | 2021-11-25 | Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230077349A true KR20230077349A (en) | 2023-06-01 |
Family
ID=86771017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210164533A KR20230077349A (en) | 2021-11-25 | 2021-11-25 | Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230077349A (en) |
-
2021
- 2021-11-25 KR KR1020210164533A patent/KR20230077349A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120128607A1 (en) | Extract of whole seeds of morninga sp, and use thereof in cosmetic and/or dermatological compositions | |
KR101312965B1 (en) | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao | |
KR100443588B1 (en) | Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect | |
KR102221033B1 (en) | Cosmetic composition for moisturizing skin comprising mixed extracts of papaver rhoeas, red clover, cimicifuga racemosa and andrographis paniculata | |
KR20130001441A (en) | Cosmetic composition containing scoria | |
KR101415996B1 (en) | Cosmetic composition containing scoria | |
KR101685251B1 (en) | Cosmetic composition comprising extract of Brassica Rapa, Brassica Rapa radish leaves or Brassica Rapa callus with anti-oxidant, astringent activity and skin wrinkle improvement effect and the manufacturing method thereof | |
KR100954695B1 (en) | Cosmetic Composition Comprising the Extract of Abelliophyllum distichum as active Ingredient | |
KR101781545B1 (en) | A cosmetic composition for skin whitening comprising the extract of saccharina japonica as active ingredient | |
KR102100345B1 (en) | A cosmetic composition comprising ligustrum lucidum extract | |
KR20170099096A (en) | Cosmetic Composition for improving Skin-Wrinkle | |
KR101934976B1 (en) | Composition for enhancing skin barrier comprising mixture of Diospyros lotus leaf extract and Curcuma longa extract as effective component | |
KR101252548B1 (en) | A cosmetic composition containing as available ingredient the extracts of Pinus koraiensis | |
KR101445642B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
KR100467081B1 (en) | Cosmetic Composition for Improving Skin Wrinkles Comprising Bergenia Emeiensis as Active Ingredient | |
KR102298449B1 (en) | A cosmetic composition comprising papaw extract and stem cell such as rock samphire callus culture extract | |
KR100744947B1 (en) | Cosmetic Composition for Skin Whitening Comprising Extract of Cnidium officinale and Protease as Active Ingredients | |
KR102168533B1 (en) | Cosmetic composition for whitening or improving the facial color containing herb extracts | |
KR20230077349A (en) | Cosmetic composition for improving skin wrinkle comprising mixed extracts of arctium lappa seed, morinda citrifolia, euphoria longana and saururus chinensis as active ingredient | |
KR101901133B1 (en) | Cosmetic composition for skin anti-wrinkle comprising Heracleum moellendorffii extract as effective component | |
KR101996547B1 (en) | Cosmetic composition with skin whitening effect containing diphylleia grayi extract | |
KR101855210B1 (en) | Cosmetic composition containing eggplant seed ultrasonicating extract of fermented by aureobasidium pullulans | |
KR20080017679A (en) | Cosmetic composition for abirritating skin containing extract of rheum undulatum as active ingredient | |
KR20150010530A (en) | A cosmetic composition comprising critical extracts of pear | |
KR102378103B1 (en) | Cosmetic Composition Comprising Fermented Extract of Morinda citrifolia and Maca Root as Active Ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal |